{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:34:27Z","timestamp":1793284467413,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Japanese Ministry of Health, Labour and Welfare","id":[{"id":"https:\/\/ror.org\/03mwa7s65","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Cancer Research and Development Fund","award":["23-A-15"],"award-info":[{"award-number":["23-A-15"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12185-026-04252-9","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:34:00Z","timestamp":1787153640000},"page":"713-722","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Voriconazole versus itraconazole for antifungal prophylaxis in patients with graft-versus-host disease: A prospective randomized trial"],"prefix":"10.1007","volume":"124","author":[{"given":"Yoshiki","family":"Hayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Nakamae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Hatanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiyoshi","family":"Moriuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Wakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Takata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Hino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9490-4669","authenticated-orcid":false,"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"4252_CR1","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1056\/NEJM199203263261301","volume":"326","author":"JL Goodman","year":"1992","unstructured":"Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845\u201351.","journal-title":"N Engl J Med"},{"key":"4252_CR2","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1093\/infdis\/171.6.1545","volume":"171","author":"MA Slavin","year":"1995","unstructured":"Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. J Infect Dis. 1995;171:1545\u201352.","journal-title":"J Infect Dis"},{"key":"4252_CR3","doi-asserted-by":"publisher","first-page":"4358","DOI":"10.1182\/blood-2002-05-1496","volume":"100","author":"KA Marr","year":"2002","unstructured":"Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood. 2002;100:4358\u201366.","journal-title":"Blood"},{"key":"4252_CR4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.7326\/0003-4819-138-9-200305060-00006","volume":"138","author":"DJ Winston","year":"2003","unstructured":"Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. Ann Intern Med. 2003;138:705\u201313.","journal-title":"Ann Intern Med"},{"key":"4252_CR5","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1182\/blood-2003-08-2644","volume":"103","author":"KA Marr","year":"2004","unstructured":"Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103:1527\u201333.","journal-title":"Blood"},{"key":"4252_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa061098","volume":"356","author":"AJ Ullmann","year":"2007","unstructured":"Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356:335\u201347.","journal-title":"N Engl J Med"},{"key":"4252_CR7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMoa061094","volume":"356","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia due to acute myelogenous leukemia or myelodysplastic syndrome: a randomized trial. N Engl J Med. 2007;356:348\u201359.","journal-title":"N Engl J Med"},{"key":"4252_CR8","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","volume":"116","author":"JR Wingard","year":"2010","unstructured":"Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, et al. Randomized, double-blind trial of fluconazole versus voriconazole for the prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116:5111\u20138.","journal-title":"Blood"},{"key":"4252_CR9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.1365-2141.2011.08838.x","volume":"155","author":"DI Marks","year":"2011","unstructured":"Marks DI, Pagliuca A, Kibbler CC, Glasmacher A, Heussel CP, Kantecki M, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011;155:318\u201327.","journal-title":"Br J Haematol"},{"key":"4252_CR10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1-60.","journal-title":"Clin Infect Dis"},{"key":"4252_CR11","first-page":"3221","volume":"73","author":"JA Maertens","year":"2018","unstructured":"Maertens JA, Girmenia C, Bruggemann RJ, Duarte RF, Kibbler CC, Ljungman P, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73:3221\u201330.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 7","key":"4252_CR12","first-page":"1","volume":"51","author":"BW Teh","year":"2021","unstructured":"Teh BW, Yeoh DK, Haeusler GM, Yannakou CK, Fleming S, Lindsay J, et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021. Intern Med J. 2021;51(Suppl 7):1\u201316.","journal-title":"Intern Med J"},{"key":"4252_CR13","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/s41375-025-02586-7","volume":"39","author":"L Pagano","year":"2025","unstructured":"Pagano L, Maschmeyer G, Lamoth F, Blennow O, Xhaard A, Spadea M, et al. Primary antifungal prophylaxis in hematological malignancies: updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL). Leukemia. 2025;39:1547\u201357.","journal-title":"Leukemia"},{"key":"4252_CR14","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"B De Pauw","year":"2008","unstructured":"De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group consensus group. Clin Infect Dis. 2008;46:1813\u201321.","journal-title":"Clin Infect Dis"},{"key":"4252_CR15","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2020;71:1367\u201376.","journal-title":"Clin Infect Dis"},{"key":"4252_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"4252_CR17","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1182\/blood-2003-02-0456","volume":"102","author":"T Fukuda","year":"2003","unstructured":"Fukuda T, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood. 2003;102:827\u201333.","journal-title":"Blood"},{"key":"4252_CR18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1086\/510592","volume":"44","author":"A Upton","year":"2007","unstructured":"Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis. 2007;44:531\u201340.","journal-title":"Clin Infect Dis"},{"key":"4252_CR19","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1093\/jac\/dkt508","volume":"69","author":"HR Ashbee","year":"2014","unstructured":"Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother. 2014;69:1162\u201376.","journal-title":"J Antimicrob Chemother"},{"key":"4252_CR20","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/jac\/dkw099","volume":"71","author":"ML Luong","year":"2016","unstructured":"Luong ML, Al-Dabbagh M, Groll AH, Racil Z, Nannya Y, Mitsani D, et al. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. J Antimicrob Chemother. 2016;71:1786\u201399.","journal-title":"J Antimicrob Chemother"},{"key":"4252_CR21","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.clinthera.2022.10.005","volume":"44","author":"Y Takesue","year":"2022","unstructured":"Takesue Y, Hanai Y, Oda K, Hamada Y, Ueda T, Mayumi T, et al. Clinical practice guideline for the therapeutic drug monitoring of voriconazole in non-Asian and Asian adult patients: consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Clin Ther. 2022;44:1604\u201323.","journal-title":"Clin Ther"},{"key":"4252_CR22","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1086\/429921","volume":"40","author":"KA Marr","year":"2005","unstructured":"Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005;40:1762\u20139.","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04252-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04252-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04252-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:53:20Z","timestamp":1793282000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04252-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["4252"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04252-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"17 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Drug supply for the study was provided by Pfizer Japan Inc. and Janssen Pharmaceutical K.K. The companies had no role in the study design; data collection, analysis, or interpretation; manuscript preparation; or the decision to submit for publication. Y.K. is an editor of International Journal of Hematology and had no role in the peer review or editorial decision-making process for this manuscript. Y.K. reports consulting fees\/honoraria from Asahi-Kasei, MSD, Pfizer, Astellas, Janssen, and Sumitomo, and research funding from Asahi-Kasei and Sumitomo. H.N. reports consulting fees\/honoraria from Astellas, Janssen, and Asahi-Kasei, and research funding from Astellas, Janssen, and Asahi-Kasei. M.T. reports consulting fees\/honoraria from Astellas, Asahi-Kasei, MSD, and Janssen. N.D. reports consulting fees\/honoraria from Asahi-Kasei, Pfizer, Janssen, Astellas, and MSD. A.K. reports consulting fees\/honoraria from Janssen. M.H. reports consulting fees\/honoraria from Astellas, Asahi-Kasei, MSD, Pfizer, and Janssen, and research funding from Asahi-Kasei and Sumitomo. T.F. reports consulting fees\/honoraria from Astellas, Sumitomo, MSD, Asahi-Kasei, and Pfizer. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated and\/or analyzed during the current study are not publicly available due to patient confidentiality and protocol-related restrictions but may be available from the corresponding author on reasonable request, subject to institutional approval.","order":2,"name":"Ethics","label":"Data availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}